PARP1 and hypertrophy: In a mouse model of type 2 diabetes (T2D), the mice exhibited increased oxidative stress, inflammation, cardiac hypertrophy, and fibrosis that was associated with enhanced PARP1 activity and decreased SIRT1 expression, while PARP1 inhibition could increase the levels of SIRT1 and PGC-1α to improve the above-mentioned adverse effects (39).